Inhibrx Biosciences, Inc.
INBX
$82.96
$0.710.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -19.26% | -24.45% | -88.78% | -88.89% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.26% | -24.45% | -88.78% | -88.89% | -- |
| Cost of Revenue | -41.80% | -37.49% | -7.08% | 19.83% | -- |
| Gross Profit | 41.95% | 37.58% | 6.40% | -20.86% | -- |
| SG&A Expenses | -58.31% | -56.10% | 322.80% | 387.80% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.09% | -43.46% | 36.19% | 68.69% | -- |
| Operating Income | 47.22% | 43.56% | -37.08% | -69.99% | -- |
| Income Before Tax | -109.45% | -110.02% | 735.43% | 799.20% | -- |
| Income Tax Expenses | 200.00% | -- | -33.33% | -33.33% | -- |
| Earnings from Continuing Operations | -109.45% | -110.02% | 735.42% | 799.19% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.45% | -110.02% | 735.42% | 799.19% | -- |
| EBIT | 47.22% | 43.56% | -37.08% | -69.99% | -- |
| EBITDA | 47.66% | 44.10% | -36.73% | -69.87% | -- |
| EPS Basic | -108.99% | -109.62% | 653.23% | 673.67% | -- |
| Normalized Basic EPS | 52.50% | 53.15% | -5.52% | -27.01% | -- |
| EPS Diluted | -109.12% | -109.77% | 645.65% | 665.61% | -- |
| Normalized Diluted EPS | 52.25% | 52.91% | -4.86% | -26.30% | -- |
| Average Basic Shares Outstanding | 8.08% | 15.49% | 22.37% | 25.62% | -- |
| Average Diluted Shares Outstanding | 7.73% | 15.08% | 22.75% | 26.02% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |